Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope

Boronic acids/esters have recently emerged in the field of medicinal and pharmaceutical research due to their exceptional oxophilicity, low toxicity, and unique structure. They are known as potent enzyme inhibitors, cancer therapy capture agents, and can mimic certain types of antibodies to fight infections. They have been designed and developed into drugs, and this approach has emerged in the last 20 years. Five boronic acid drugs have been approved by the FDA and Health Canada, two of which are used to treat cancer, specifically multiple myeloma. The purpose of this review is to investigate boronic acid/ester derivatives as potential pharmaceutical agents as well as the mechanism of action. It will concentrate on six types of cancer: multiple myeloma, prostate cancer, breast cancer, lung cancer, cervical cancer, and colon cancer. Some newly developed boron-containing compounds have already demonstrated highly promising activities, but further investigation is required before final conclusions can be drawn.

Automated summary

Boronic acids/esters have gained significant attention in medicinal and pharmaceutical research due to their unique structure, low toxicity, and ability to inhibit enzymes, capture cancer cells, and mimic certain types of antibodies. This review focuses on the potential of boronic acid/ester derivatives as pharmaceutical agents for treating multiple myeloma, prostate cancer, breast cancer, lung cancer, cervical cancer, and colon cancer. Although some newly developed boron-containing compounds have shown promising activities, further investigation is necessary before definitive conclusions can be drawn.